Covance
|
Covance Inc. (NYSE: CVD), with headquarters in Princeton, NJ, is one of the world's largest and most comprehensive drug development services companies with annual revenues of over $1.5 billion, operations in 20 countries, and over 8,700 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained at http://www.covance.com.
Worldwide, Covance helps pharmaceutical and biotech companies fulfill their research and development, clinical trial, regulatory and marketing-support needs. Covance offers comprehensive, biopharmaceutical development services including polyclonal production, hybridoma development, in vitro production, ascite...
More from Zoominfo » |
How to get a job at Covance.
- 5 Replies
Do you work at Covance? How did you find the job? How did you get that first interview?
Any advice for someone trying to get in?
Covance Salaries, Bonuses and Benefits.
- 2 Replies
What are the average starting salaries, bonuses, benefits and travel requirements like at Covance?
What do you like best about working at Covance? ...
Covance Interview Questions.
It's always hard to know what to expect when going in for that interview -- and preparation can make all the difference. What is the interview...
What's the company culture at Covance?
Every business has its own style. What is the office environment and culture like at Covance?
Are people dressed in business casual, jeans and...
Covance News and Gossip.
What do you think - will Covance grow fast? Are they expanding their staff? How does Covance stack up against the competition?
More Covance discussions
|
|
TCW: Lowered Guidance Won’t Stop Covance
The Princeton, N.J.-based company lowered its full-year 2008 guidance in late December, after experiencing a slower-than-expected fourth quarter. The CRO expects its full-year earnings per share to be $3.02 with “low double-digit” ...
From
CenterWatch's Clinical Trials ...
- 2 days ago
Dividend Stocks - The Dividend Daily » Blog Archive » Covance ...
Shares are down over 60% in the last three months, so investors should not be shocked by the company’s lowered guidance. The stock does have technical support in the $30 price area. If that fails to hold, the $17-19 area would be the ...
From
Dividend Stocks - The Dividend...
- by Dividend.com - 21 days ago
GenomeWeb News: Covance Buys Caprion Proteomics Equity Stake
NEW YORK (GenomeWeb News) – Princeton, NJ-based drug development services company Covance announced yesterday that it has purchased an undisclosed minority stake in the proteomics-based pharmaceutical services company Caprion Proteomics ...
From
GenomeWeb Daily News Current I...
- 22 days ago
More blog posts from Google Blog Search
|
|
